Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 480

1.

Quantitative Systems Pharmacology Model for Alzheimer's Disease Indicates Targeting Sphingolipid Dysregulation as Potential Treatment Option.

Clausznitzer D, Pichardo-Almarza C, Relo AL, van Bergeijk J, van der Kam E, Laplanche L, Benson N, Nijsen M.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep 12. doi: 10.1002/psp4.12351. [Epub ahead of print]

2.

Importance of feedback and feedforward loops to adaptive immune response modeling.

Rahman A, Tiwari A, Narula J, Hickling T.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep 10. doi: 10.1002/psp4.12352. [Epub ahead of print] Review.

3.

Predicting the Onset of Nonlinear Pharmacokinetics.

Stein AM, Peletier LA.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep 8. doi: 10.1002/psp4.12316. [Epub ahead of print]

4.

PBPK modeling of coproporphyrin I as an endogenous biomarker for drug interactions involving inhibition of hepatic OATP1B1 and OATP1B3.

Yoshikado T, Toshimoto K, Maeda K, Kusuhara H, Kimoto E, David Rodrigues A, Chiba K, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep 3. doi: 10.1002/psp4.12348. [Epub ahead of print]

5.

Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate.

Kaddurah-Daouk R, Hankemeier T, Scholl EH, Baillie R, Harms A, Stage C, Dalhoff KP, Jűrgens G, Taboureau O, Nzabonimpa GS, Motsinger-Reif AA, Thomsen R, Linnet K, Rasmussen HB; INDICES Consortium; Pharmacometabolomics Research Network.

CPT Pharmacometrics Syst Pharmacol. 2018 Aug;7(8):525-533. doi: 10.1002/psp4.12309.

6.

Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug Interaction Between S-ketamine and Ticlopidine in Healthy Human Volunteers.

Ashraf MW, Peltoniemi MA, Olkkola KT, Neuvonen PJ, Saari TI.

CPT Pharmacometrics Syst Pharmacol. 2018 Aug 9. doi: 10.1002/psp4.12346. [Epub ahead of print]

7.

Three-Component Mixture Model-Based Adverse Drug Event Signal Detection for the Adverse Event Reporting System.

Zhang P, Li M, Chiang CW, Wang L, Xiang Y, Cheng L, Feng W, Schleyer TK, Quinney SK, Wu HY, Zeng D, Li L.

CPT Pharmacometrics Syst Pharmacol. 2018 Aug;7(8):499-506. doi: 10.1002/psp4.12294. Epub 2018 Aug 9.

8.

PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.

Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T.

CPT Pharmacometrics Syst Pharmacol. 2018 Aug 8. doi: 10.1002/psp4.12343. [Epub ahead of print]

9.

A Partial Differential Equation Approach to Inhalation Physiologically Based Pharmacokinetic Modeling.

Boger E, Wigström O.

CPT Pharmacometrics Syst Pharmacol. 2018 Aug 7. doi: 10.1002/psp4.12344. [Epub ahead of print]

10.

Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.

Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Aug 7. doi: 10.1002/psp4.12320. [Epub ahead of print]

11.

Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans.

Guiastrennec B, Sonne DP, Bergstrand M, Vilsbøll T, Knop FK, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2018 Aug 2. doi: 10.1002/psp4.12325. [Epub ahead of print]

12.

A Regression Approach to Visual Predictive Checks for Population Pharmacometric Models.

Jamsen KM, Patel K, Nieforth K, Kirkpatrick CMJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul 29. doi: 10.1002/psp4.12319. [Epub ahead of print]

13.

Allometric Considerations on Proteins Administered Intravitreally to Children.

Eissing T.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul 27. doi: 10.1002/psp4.12342. [Epub ahead of print] No abstract available.

14.

Modulation of Cell State to Improve Drug Therapy.

Gallo JM.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul 24. doi: 10.1002/psp4.12317. [Epub ahead of print] No abstract available.

15.

Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect.

Mulyukov Z, Weber S, Pigeolet E, Clemens A, Lehr T, Racine A.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul 24. doi: 10.1002/psp4.12322. [Epub ahead of print]

16.

Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects.

van Esdonk MJ, Lindeman I, Okkerse P, de Kam ML, Groeneveld GJ, Stevens J.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul 24. doi: 10.1002/psp4.12318. [Epub ahead of print]

17.

A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.

Biliouris K, Gaitonde P, Yin W, Norris DA, Wang Y, Henry S, Fey R, Nestorov I, Schmidt S, Rogge M, Lesko LJ, Trame MN.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul 24. doi: 10.1002/psp4.12323. [Epub ahead of print]

18.

Automated Scale Reduction of Nonlinear QSP Models With an Illustrative Application to a Bone Biology System.

Hasegawa C, Duffull SB.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul 24. doi: 10.1002/psp4.12324. [Epub ahead of print]

19.

Development of a Dynamic Physiologically Based Mechanistic Kidney Model to Predict Renal Clearance.

Huang W, Isoherranen N.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul 24. doi: 10.1002/psp4.12321. [Epub ahead of print]

20.

Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO.

Watt KM, Cohen-Wolkowiez M, Barrett JS, Sevestre M, Zhao P, Brouwer KLR, Edginton AN.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul 22. doi: 10.1002/psp4.12338. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center